Zacks Investment Research upgraded shares of Zymeworks Inc. (NYSE:ZYME) from a hold rating to a buy rating in a research note published on Tuesday. They currently have $7.75 price objective on the stock.
According to Zacks, “Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada. “
Other analysts have also recently issued research reports about the stock. Cormark reaffirmed a buy rating on shares of Zymeworks in a research note on Saturday, September 30th. Scotiabank lowered shares of Zymeworks from an overweight rating to an underweight rating in a research report on Thursday, September 7th. Finally, Barclays PLC reiterated an underweight rating and set a $8.00 target price on shares of Zymeworks in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $14.35.
TRADEMARK VIOLATION NOTICE: “Zymeworks Inc. (ZYME) Lifted to Buy at Zacks Investment Research” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/17/zymeworks-inc-zyme-lifted-to-buy-at-zacks-investment-research.html.
Several hedge funds have recently modified their holdings of the company. OxFORD Asset Management LLP acquired a new stake in Zymeworks in the 2nd quarter worth about $154,000. Franklin Resources Inc. acquired a new position in shares of Zymeworks during the 2nd quarter valued at $6,878,000. Sentry Investments Corp. acquired a new position in shares of Zymeworks during the 2nd quarter valued at $206,000. Finally, Barometer Capital Management Inc. acquired a new position in shares of Zymeworks during the 2nd quarter valued at $484,000. 8.17% of the stock is owned by institutional investors.
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Zymeworks Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zymeworks Inc. and related companies.